Hot Investor Mandate: Life Science VC Firm with USA and China Offices Invests in Novel Therapeutics, Including Small Molecules, Biologics, etc.

17 Oct

A life science venture capital firm with strong China expertise and global capabilities was founded in 2017. The firm discovers, incubates and grows next-generation life science companies in early and growth stage, worldwide. Their portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs.

The firm currently has two funds: The first $115 million fund has been fully invested. The firm is raising another $115 million fund, which more than half are closed. The firm operates offices in USA and China.

The firm focuses mostly on novel therapeutics, like small molecule, cell therapy, gene therapy, etc, while the firm is also open to enabling technologies and high-end specialty services. The firm is looking to invest from seed, first institutional round, to growth stage.

The firm has no specific requirement for the company & management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Global Technology Company Seeks Partnerships and Licensing Opportunities in Promising Medical Device Startups

17 Oct

A global technology company is dedicated to crafting innovative optical and digital solutions in medical technologies; life sciences; industrial solutions; and cameras and audio products.

The company’s medical business works with health care professionals to combine their innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing with their skills to deliver diagnostic, therapeutic and minimally invasive procedures to improve clinical outcomes, reduce overall costs and enhance quality of life for patients.

Throughout the company’s long history, the company has focused on being true to society and making people’s lives healthier, safer and more fulfilling. The company’s commitment to our purpose along with our major presence in hospitals around the world aligns with our goal to invest in future developments that will improve the experiences of providers and patients and transform Healthcare around the world.

The company is seeking partnerships and licensing relationships with early stage medical device startups worldwide. The company’s key areas of interest are endoscopes, laparoscopic devices, devices for minimally invasive surgery, and AI technologies across a wide range of specialties including ENT, gastrointestinal, respiratory, gynecology, and urology.

The company is interested in working with and supporting medical device companies with differentiated technology addressing unmet medical needs. An ideal partner would have an experienced management team with a proven track record of successful business development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Firm with Headquarters in Southeast Asia Makes Seed to Series B Investments Across Various Life Science Technologies, Including AI, Consumer Health, etc.

17 Oct

Founded in 2011, a venture capital firm based in Southeast Asia makes Seed to Series B investments across several key sectors including healthcare, fintech, consumer, AI, and life science services. The firm manages $200 million, and is investing from its second fund. While the firm focuses on their home country, the firm is looking for opportunities worldwide and has recently made an investment in the USA.

The firm will consider a wide variety of life science opportunities. The firm’s past investments have included pharma supply chain, AI, and healthcare services.

The firm seeks a strong and experienced management team, with a focus on entrepreneurs from elite educational institutions.  The firm focuses on India and has a strong connection with major academic institutions in their country of origin, but looks worldwide for novel technology breakthroughs to invest in.  The firm has also launched a Unified Innovation and Entrepreneurship Platform to incubate new startups.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Venture Firm with USA and China Offices Invests in Highly Disruptive Technologies Within All Life Science Sectors

17 Oct

A venture capital firm founded in 2015 and based in the USA also has a partner in China that can provide support to companies interested in China market entry, but companies do not need to have a China angle. The firm has great experience with working with regulatory agencies to gain product approval for both FDA and CFDA. Since its establishment, the firm has invested in over 30 companies and continues to actively seek life science investments, aiming to invest in 8-10 companies per year. The firm usually participates in seed to series B financing rounds with check sizes between $500K – 2M and will consider companies based in USA and China.

The firm is opportunistic and will consider all early-stage opportunities in therapeutics, medical devices, diagnostics, and digital health, as long as the technology is considered highly disruptive. The firm’s greatest focus lies in the medical device sector in which the firm has the strongest expertise. In therapeutics, the firm will consider pre-clinical and phase I assets. In medical devices and diagnostics, the firm is open to all classes of medical devices including 510k and PMA that are in development or clinical trials. The firm has reviewed companies of various stages in the past: those that have just developed a valid prototype, and those that were already profitable prior to investment.

The firm seeks to work with companies with an experienced management team, ideally led by a serial entrepreneur with a successful track record. The firm can both lead and co-invest but prefers to lead financing rounds for medical device companies and will most likely take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Global Family Office BioForum Joins RESI Asia

10 Oct

Interview with Chuck Stetson, CEO of Stetson Family Office

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Click to see part one of a two part interview with Chuck Stetson, CEO, Stetson Family Office and Founder of the Global Family Office BioForum (GFOB). Chuck, who is the third generation running the Stetson Family Office, is an entrepreneur, venture capitalist, and philanthropist. GFOB helps make more high quality investments in the life science arena by connecting regional family offices with regional angel groups, incubators and accelerators – essentially helping family offices around the globe participate in the funding of early stage technology assets located in their local healthcare tech hubs.

This interview, conducted by Dennis Ford, CEO, Life Science Nation and Creator of the Redefining Early Stage Investments (RESI) Conference Series, is a deep dive into how a family office views and participates in funding startups.  Chuck will be representing the GFOB at both RESI Asia events – Shanghai, November 12th and Taipei, November 14th. Click here to register for the events.

FOUR Chances to Present at RESI Asia!

10 Oct

By Gregory Mannix, Vice President International Business Development, LSN

That’s right – RESI Asia will, for the first time, allow participants to present their companies four times over the course of two days. By applying to the Innovation Challenge for RESI Asia, companies will get the chance to present a poster in the exhibition hall AND pitch to a panel of investors at both the Shanghai RESI conference on November 12th and the Taipei RESI conference on November 14th. That is an incredible opportunity to get visibility for your company and meet with many investors and strategics from China, Asia-Pacific and beyond.

We know from experience that companies that compete as finalists in the Innovation Challenge at a RESI conference get more visibility and more one-on-one meetings with investors. The opportunity this November, with two conferences back-to-back in two hot life science hubs in Asia, is UNPRECEDENTED.

As always, participating in the RESI Innovation Challenge carries no additional cost for companies. You’ve got nothing to lose, and everything to gain!

New Healthcare Breakthroughs From All Over the World on Show at RESI Asia

10 Oct

By Lucy Parkinson, VP of Investor Research, LSN

When LSN decided to bring RESI to Asia, we aimed to provide far more than a regional networking hub. Through our relationships with investors and technology hubs worldwide, we knew that many investment firms are looking to Asia as a source of new technologies – and conversely, many investors and major corporations based in Asia want to meet early stage startups from other parts of the world.

Due to the outreach LSN’s team has performed to technology hubs and early stage companies, RESI Asia is building up to a global showcase of early stage drugs, devices, diagnostics, and digital health innovations. We hope you can join us in Shanghai and Taipei to meet these entrepreneurs face to face.

RESI ASIA Therapeutics Companies
RESI ASIA Medical Device Companies
 
RESI ASIA Diagnostics Companies
 
RESI ASIA Digital Health Companies
 
RESI ASIA Service Providers

And More…

← Older Entries
Newer Entries →